These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 31114804

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37.
    Sadeghi S, Bakhshandeh H, Ahangari Cohan R, Peirovi A, Ehsani P, Norouzian D.
    Int J Nanomedicine; 2019; 14():9777-9792. PubMed ID: 31849468
    [Abstract] [Full Text] [Related]

  • 23. Non-invasive tri-modal visualisation via PET/SPECT/μCT of recombinant human bone morphogenetic protein-2 retention and associated bone regeneration: A proof of concept.
    Hulsart-Billström G, Selvaraju RK, Estrada S, Lubberink M, Asplund V, Bergman K, Marsell R, Larsson S, Antoni G.
    J Control Release; 2018 Sep 10; 285():178-186. PubMed ID: 30005906
    [Abstract] [Full Text] [Related]

  • 24. Tuning physical properties and BMP-2 release rates of injectable hydrogel systems for an optimal bone regeneration effect.
    Seo BB, Koh JT, Song SC.
    Biomaterials; 2017 Apr 10; 122():91-104. PubMed ID: 28110173
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China.
    Yang XY, Li CR, Lou RH, Wang YM, Zhang WX, Chen HZ, Huang QS, Han YX, Jiang JD, You XF.
    J Med Microbiol; 2007 Jan 10; 56(Pt 1):71-76. PubMed ID: 17172520
    [Abstract] [Full Text] [Related]

  • 27. Delivery vehicle effects on bone regeneration and heterotopic ossification induced by high dose BMP-2.
    Krishnan L, Priddy LB, Esancy C, Klosterhoff BS, Stevens HY, Tran L, Guldberg RE.
    Acta Biomater; 2017 Feb 10; 49():101-112. PubMed ID: 27940197
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Development of chitosan-collagen hydrogel incorporated with lysostaphin (CCHL) burn dressing with anti-methicillin-resistant Staphylococcus aureus and promotion wound healing properties.
    Cui F, Li G, Huang J, Zhang J, Lu M, Lu W, Huan J, Huang Q.
    Drug Deliv; 2011 Apr 10; 18(3):173-80. PubMed ID: 20726806
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Evaluation of the antimicrobial activity of lysostaphin-coated hernia repair meshes.
    Satishkumar R, Sankar S, Yurko Y, Lincourt A, Shipp J, Heniford BT, Vertegel A.
    Antimicrob Agents Chemother; 2011 Sep 10; 55(9):4379-85. PubMed ID: 21709102
    [Abstract] [Full Text] [Related]

  • 32. Regeneration of calvarial defects with Escherichia coli -derived rhBMP-2 adsorbed in PLGA membrane.
    Ono M, Sonoyama W, Nema K, Hara ES, Oida Y, Pham HT, Yamamoto K, Hirota K, Sugama K, Sebald W, Kuboki T.
    Cells Tissues Organs; 2013 Sep 10; 198(5):367-76. PubMed ID: 24434422
    [Abstract] [Full Text] [Related]

  • 33. Antibody-directed targeting of lysostaphin adsorbed onto polylactide nanoparticles increases its antimicrobial activity against S. aureus in vitro.
    Satishkumar R, Vertegel AA.
    Nanotechnology; 2011 Dec 16; 22(50):505103. PubMed ID: 22107797
    [Abstract] [Full Text] [Related]

  • 34. Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin.
    Walencka E, Sadowska B, Rózalska S, Hryniewicz W, Rózalska B.
    Folia Microbiol (Praha); 2006 Dec 16; 51(5):381-6. PubMed ID: 17176756
    [Abstract] [Full Text] [Related]

  • 35. Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.
    Zhao H, Verma D, Li W, Choi Y, Ndong C, Fiering SN, Bailey-Kellogg C, Griswold KE.
    Chem Biol; 2015 May 21; 22(5):629-39. PubMed ID: 26000749
    [Abstract] [Full Text] [Related]

  • 36. Skull bone regeneration in nonhuman primates by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel.
    Takahashi Y, Yamamoto M, Yamada K, Kawakami O, Tabata Y.
    Tissue Eng; 2007 Feb 21; 13(2):293-300. PubMed ID: 17504062
    [Abstract] [Full Text] [Related]

  • 37. Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects.
    Boyne PJ.
    J Bone Joint Surg Am; 2001 Feb 21; 83-A Suppl 1(Pt 2):S146-50. PubMed ID: 11314792
    [Abstract] [Full Text] [Related]

  • 38. Site-specific N-glycosylation of caprine lysostaphin restricts its bacteriolytic activity toward Staphylococcus aureus.
    Huang CY, Hsu JT, Chung PH, Cheng WT, Jiang YN, Ju YT.
    Anim Biotechnol; 2013 Feb 21; 24(2):129-47. PubMed ID: 23534959
    [Abstract] [Full Text] [Related]

  • 39. Immobilization of recombinant lysostaphin on nanoparticle through biotin-streptavidin conjugation technology as a geometrical progressed confrontation against Staphylococcus aureus infection.
    Ehsani G, Farahnak M, Norouzian D, Ehsani P.
    Biotechnol Appl Biochem; 2021 Oct 21; 68(5):1058-1066. PubMed ID: 32918836
    [Abstract] [Full Text] [Related]

  • 40. BMP-2 delivered from a self-crosslinkable CaP/hydrogel construct promotes bone regeneration in a critical-size segmental defect model of non-union in dogs.
    Minier K, Touré A, Fusellier M, Fellah B, Bouvy B, Weiss P, Gauthier O.
    Vet Comp Orthop Traumatol; 2014 Oct 21; 27(6):411-21. PubMed ID: 25327869
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.